Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of Euro...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Anja Vogt [verfasserIn] Ursula Kassner [verfasserIn] Ulrike Hostalek [verfasserIn] Elisabeth Steinhagen-Thiessen [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2007

Übergeordnetes Werk:	In: Vascular Health and Risk Management - Dove Medical Press, 2009, (2007), Issue 4, Seite 467-479
Übergeordnetes Werk:	year:2007 ; number:Issue 4 ; pages:467-479

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ022905170

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ022905170
003	DE-627
005	20230307062033.0
007	cr uuu---uuuuu
008	230226s2007 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ022905170
035			\|a (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC666-701
100	0		\|a Anja Vogt \|e verfasserin \|4 aut
245	1	0	\|a Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
264		1	\|c 2007
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk
653		0	\|a Diseases of the circulatory (Cardiovascular) system
700	0		\|a Ursula Kassner \|e verfasserin \|4 aut
700	0		\|a Ulrike Hostalek \|e verfasserin \|4 aut
700	0		\|a Elisabeth Steinhagen-Thiessen \|e verfasserin \|4 aut
773	0	8	\|i In \|t Vascular Health and Risk Management \|d Dove Medical Press, 2009 \|g (2007), Issue 4, Seite 467-479 \|w (DE-627)481905839 \|w (DE-600)2180578-7 \|x 11782048 \|7 nnns
773	1	8	\|g year:2007 \|g number:Issue 4 \|g pages:467-479
856	4	0	\|u https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 \|z kostenfrei
856	4	0	\|u http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1176-6344 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-2048 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2007 \|e Issue 4 \|h 467-479

Indexfelder

author_variant	a v av u k uk u h uh e s t est
matchkey_str	article:11782048:2007----::rlnerlaeioiiaifrhmngmnodsiieiaudticui
hierarchy_sort_str	2007
callnumber-subject-code	RC
publishDate	2007
allfields	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479
spelling	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479
allfields_unstemmed	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479
allfieldsGer	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479
allfieldsSound	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889 DE-627 ger DE-627 rakwb eng RC666-701 Anja Vogt verfasserin aut Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study 2007 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk Diseases of the circulatory (Cardiovascular) system Ursula Kassner verfasserin aut Ulrike Hostalek verfasserin aut Elisabeth Steinhagen-Thiessen verfasserin aut In Vascular Health and Risk Management Dove Medical Press, 2009 (2007), Issue 4, Seite 467-479 (DE-627)481905839 (DE-600)2180578-7 11782048 nnns year:2007 number:Issue 4 pages:467-479 https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 kostenfrei http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 kostenfrei https://doaj.org/toc/1176-6344 Journal toc kostenfrei https://doaj.org/toc/1178-2048 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2007 Issue 4 467-479
language	English
source	In Vascular Health and Risk Management (2007), Issue 4, Seite 467-479 year:2007 number:Issue 4 pages:467-479
sourceStr	In Vascular Health and Risk Management (2007), Issue 4, Seite 467-479 year:2007 number:Issue 4 pages:467-479
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Diseases of the circulatory (Cardiovascular) system
isfreeaccess_bool	true
container_title	Vascular Health and Risk Management
authorswithroles_txt_mv	Anja Vogt @@aut@@ Ursula Kassner @@aut@@ Ulrike Hostalek @@aut@@ Elisabeth Steinhagen-Thiessen @@aut@@
publishDateDaySort_date	2007-01-01T00:00:00Z
hierarchy_top_id	481905839
id	DOAJ022905170
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022905170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307062033.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022905170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anja Vogt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (&lt;1.02 mmol/L [40 mg/dL] in men or &lt;1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan&reg; (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan&reg; have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan&reg; in a usual-care setting. The most common side-effect of Niaspan&reg; is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1&ndash;2 years of treatment with Niaspan&reg; plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan&reg;-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan&reg; represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan&reg;, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursula Kassner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrike Hostalek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabeth Steinhagen-Thiessen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vascular Health and Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2007), Issue 4, Seite 467-479</subfield><subfield code="w">(DE-627)481905839</subfield><subfield code="w">(DE-600)2180578-7</subfield><subfield code="x">11782048</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2007</subfield><subfield code="g">number:Issue 4</subfield><subfield code="g">pages:467-479</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1176-6344</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2048</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2007</subfield><subfield code="e">Issue 4</subfield><subfield code="h">467-479</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Anja Vogt
spellingShingle	Anja Vogt misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
authorStr	Anja Vogt
ppnlink_with_tag_str_mv	@@773@@(DE-627)481905839
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC666-701
illustrated	Not Illustrated
issn	11782048
topic_title	RC666-701 Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
topic	misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system
topic_unstemmed	misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system
topic_browse	misc RC666-701 misc Diseases of the circulatory (Cardiovascular) system
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Vascular Health and Risk Management
hierarchy_parent_id	481905839
hierarchy_top_title	Vascular Health and Risk Management
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)481905839 (DE-600)2180578-7
title	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
ctrlnum	(DE-627)DOAJ022905170 (DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889
title_full	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
author_sort	Anja Vogt
journal	Vascular Health and Risk Management
journalStr	Vascular Health and Risk Management
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2007
contenttype_str_mv	txt
container_start_page	467
author_browse	Anja Vogt Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen
class	RC666-701
format_se	Elektronische Aufsätze
author-letter	Anja Vogt
author2-role	verfasserin
title_sort	prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the nautilus study
callnumber	RC666-701
title_auth	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
abstract	Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk
abstractGer	Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk
abstract_unstemmed	Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan® (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan® have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan® in a usual-care setting. The most common side-effect of Niaspan® is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1–2 years of treatment with Niaspan® plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan®-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan® represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan®, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	Issue 4
title_short	Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study
url	https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889 http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496 https://doaj.org/toc/1176-6344 https://doaj.org/toc/1178-2048
remote_bool	true
author2	Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen
author2Str	Ursula Kassner Ulrike Hostalek Elisabeth Steinhagen-Thiessen
ppnlink	481905839
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC666-701
up_date	2024-07-03T14:39:58.490Z
_version_	1803569173361590272
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ022905170</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230307062033.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230226s2007 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ022905170</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJeaad1f51e684402f8980fdc73b0f7889</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Anja Vogt</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Anja Vogt1, Ursula Kassner1, Ulrike Hostalek2, Elisabeth Steinhagen-Thiessen11Charite-Universitatsmedizin Berlin, Germany; 2Merck KGaA, Darmstadt, GermanyAbstract: Low HDL-cholesterol (&lt;1.02 mmol/L [40 mg/dL] in men or &lt;1.29 mmol/L [50 mg/dL] in women) occurs in about one-third of European patients with dyslipidemia and is an independent cardiovascular risk factor. Simultaneous correction of low HDL-cholesterol and high totalcholesterol and LDL-cholesterol may provide reductions in cardiovascular morbidity and mortality beyond those possible with statins alone. Nicotinic acid (niacin in the US) is the most effective means of increasing HDL-cholesterol available and has been shown to reduce cardiovascular event rates significantly. Niaspan&reg; (prolonged-release nicotinic acid) provides a convenient, once-daily means of administering nicotinic acid. Clinical studies with Niaspan&reg; have demonstrated marked, long-term increases in HDL-cholesterol with additional useful benefits on triglycerides, LDLcholesterol, and lipid sub-profiles. The NAUTILUS study demonstrated the beneficial efficacy and tolerability profiles of Niaspan&reg; in a usual-care setting. The most common side-effect of Niaspan&reg; is flushing, which infrequently causes treatment discontinuation and which usually subsides over continued treatment. The ARBITER 2 and ARBITER 3 studies showed 1&ndash;2 years of treatment with Niaspan&reg; plus a statin induced regression of atherosclerosis in patients with coronary artery disease. The effect of Niaspan&reg;-statin treatment, relative to a statin alone, on clinical cardiovascular outcomes is currently under evaluation. Niaspan&reg; represents a practical means of correcting low HDL-cholesterol, an independent risk factor for adverse cardiovascular outcomes.Keywords: prolonged-release nicotinic acid, Niaspan&reg;, niacin, dyslipidemia, HDL-cholesterol cardiovascular risk</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ursula Kassner</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ulrike Hostalek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Elisabeth Steinhagen-Thiessen</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Vascular Health and Risk Management</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2007), Issue 4, Seite 467-479</subfield><subfield code="w">(DE-627)481905839</subfield><subfield code="w">(DE-600)2180578-7</subfield><subfield code="x">11782048</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2007</subfield><subfield code="g">number:Issue 4</subfield><subfield code="g">pages:467-479</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/eaad1f51e684402f8980fdc73b0f7889</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/prolonged-release-nicotinic-acid-for-the-management-of-dyslipidemia-an-a1496</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1176-6344</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-2048</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2007</subfield><subfield code="e">Issue 4</subfield><subfield code="h">467-479</subfield></datafield></record></collection>
score	7.4007425

Nicht das Richtige dabei?

Schreiben Sie uns!

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?